Mounjaro vs Ozempic: Constipation Comparison
Mounjaro (tirzepatide) causes more constipation than Ozempic (semaglutide). Based on the most recent head-to-head trial data, constipation occurs in approximately 5% of patients on tirzepatide compared to less frequent rates with semaglutide 1, 2.
Direct Comparison Evidence
In the SURPASS-2 trial, which directly compared tirzepatide to semaglutide in patients with type 2 diabetes, constipation was not among the most common gastrointestinal side effects for either medication 3. However, systematic analysis reveals important differences:
- Tirzepatide constipation rate: 2.54-5% across clinical trials 1, 4
- Semaglutide constipation rate: Approximately 5-10% in obesity trials, though this varies by dose 1, 2
Meta-Analysis Findings
A 2023 systematic review and meta-analysis specifically examining tirzepatide's gastrointestinal effects found that constipation occurred in 2.54% of tirzepatide patients versus 0.856% in comparator groups (which included semaglutide), representing a 3-fold increased risk (RR 3.08; 95% CI 1.83-5.20) 4.
Clinical Context and Dosing Considerations
The constipation rates must be interpreted in context of dosing patterns:
- Most patients (83.5%) on semaglutide 2.4 mg reach maximum dose, while only 25.9% on tirzepatide reach the 15 mg maximum dose 5
- Both medications cause dose-dependent gastrointestinal effects that are typically mild-to-moderate and occur primarily during dose escalation 1, 2, 3
Relative Gastrointestinal Side Effect Profile
While constipation is a concern, it's important to note the overall GI side effect hierarchy:
For tirzepatide:
- Nausea: 20.43% (most common)
- Diarrhea: 16.24%
- Vomiting: 9.05%
- Decreased appetite: 9.64%
- Dyspepsia: 7.13%
- Constipation: 2.54% 4
For semaglutide:
Clinical Management Recommendations
If constipation is a primary concern when choosing between these medications:
- Consider starting with semaglutide if the patient has pre-existing constipation or risk factors 1, 2
- Use slow dose titration for either medication to minimize all GI side effects, including constipation 6, 7
- Counsel patients that GI effects are typically transient and occur during dose escalation 1, 2
- Consider prophylactic measures such as adequate hydration, dietary fiber, and potentially magnesium oxide supplementation 8
Important Caveats
The constipation data shows considerable variability across trials, likely due to:
- Different patient populations (diabetes vs. obesity-only)
- Varying dose escalation protocols
- Different comparator groups
- Reporting methodology differences 4, 3, 5
Both medications share the same mechanism of delayed gastric emptying through GLP-1 receptor activation, which theoretically could contribute to constipation, though paradoxically diarrhea is more common 9, 6.